Skip to content

Twitter page opens in new window Linkedin page opens in new window Instagram page opens in new window

investorenquiries@pharmaust.com+61 8 9202 6814

PharmAust (PAA)

HOME
ABOUT
PIPELINE & TRIALS
INVESTOR CENTRE
MEDIA
CONTACT

HOME
ABOUT
PIPELINE & TRIALS
INVESTOR CENTRE
MEDIA
CONTACT

December 13, Shareholder Update and Strategy

13 211213_ShareholderUpdateandStrategy_

Category: News and Announcements 2021By PharmAust December 13, 2021

Related posts

December 15, Epichem Awarded DNDi Extension
December 15, 2021

December 1, Demonstration Batch Small MPL Tablets Completed
December 1, 2021

December 1, Top 20 Shareholders
December 1, 2021

November 17, FightMND and COVID-19 Trials on Track
November 17, 2021

November 15, New Zealand Joins Phase 2B Pet Dog Trial
November 15, 2021

November 1, Top 20 Shareholders
November 1, 2021

Recent Articles

Canine Cancer Trial Update
March 27, 2023
Free Biotech & Nutrition Investor Webinar
March 17, 2023
First Patient of Cohort 2 Dosed in MND Trial 3 market sensitive
February 20, 2023
PharmAust canine trial update 18 market sensitive
February 10, 2023

MENU

Home
About Us
Pipeline & Trials
Investor Centre
Media
Contact Us

SUBSCRIBE TO OUR NEWSLETTER

Leave this field empty if you're human:

TWITTER

PharmAust Follow

PharmAust is a clinical-stage biotech company developing drug discovery IP to treat cancer, viral and neurological diseases. ASX: $PAA FSE: $ECQ

PharmAust @pharmaust ·

17h

Write up on $PAA/@PharmAust in today's @Australian @aus_business

Reply on Twitter 1640893023193284609 Retweet on Twitter 1640893023193284609 2 Like on Twitter 1640893023193284609 11 Twitter 1640893023193284609

PharmAust @pharmaust ·

20h

PharmAust announces protocol deviation in trial of MPL for motor neurone disease
via @biotechdispatch https://biotechdispatch.com.au/news/stable-patient-in-cohort-1-of-mnd-trial-reaches-6-months-on-mpl

Reply on Twitter 1640844556324442114 Retweet on Twitter 1640844556324442114 3 Like on Twitter 1640844556324442114 11 Twitter 1640844556324442114

PharmAust @pharmaust ·

28 Mar

PharmAust’s MND trial progressing with ‘stable’ patient moving to higher dosage
https://stockhead.com.au/health/pharmausts-mnd-trial-progressing-with-stable-patient-moving-to-higher-dosage/

Reply on Twitter 1640560766570082304 Retweet on Twitter 1640560766570082304 5 Like on Twitter 1640560766570082304 10 Twitter 1640560766570082304

Load More

Copyright © 2023 PharmAust. All rights reserved.

nil

Website Design & Digital Marketing Perth by Total Click Solutions